{"id":"NCT01809327","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","officialTitle":"A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-06-04","primaryCompletion":"2014-12-02","completion":"2014-12-02","firstPosted":"2013-03-12","resultsPosted":"2016-01-06","lastUpdate":"2017-07-11"},"enrollment":1186,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Canagliflozin 100 mg","otherNames":[]},{"type":"DRUG","name":"Canagliflozin 300 mg","otherNames":[]},{"type":"DRUG","name":"Metformin XR","otherNames":[]}],"arms":[{"label":"Canagliflozin 100 mg","type":"EXPERIMENTAL"},{"label":"Canagliflozin 300 mg","type":"EXPERIMENTAL"},{"label":"Metformin XR","type":"EXPERIMENTAL"},{"label":"Canagliflozin 100 mg + Metformin XR","type":"EXPERIMENTAL"},{"label":"Canagliflozin 300 mg + Metformin XR","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to assess the effectiveness of the co-administration of canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and metformin XR alone in patients with type 2 diabetes mellitus with inadequate control despite treatment with diet and exercise. The safety and tolerability of canagliflozin will also be assessed.","primaryOutcome":{"measure":"Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26","timeFrame":"Day 1 (Baseline) and Week 26","effectByArm":[{"arm":"Metformin XR","deltaMin":-1.3,"sd":0.071},{"arm":"Canagliflozin 100 Milligram (mg)","deltaMin":-1.37,"sd":0.071},{"arm":"Canagliflozin 300 mg","deltaMin":-1.42,"sd":0.07},{"arm":"Canagliflozin 100 mg + Metformin XR","deltaMin":-1.77,"sd":0.069},{"arm":"Canagliflozin 300 mg + Metformin XR","deltaMin":-1.78,"sd":0.07}],"pValues":[{"comp":"OG000 vs OG003","p":"0.001"},{"comp":"OG000 vs OG004","p":"0.001"},{"comp":"OG001 vs OG003","p":"0.001"},{"comp":"OG002 vs OG004","p":"0.001"},{"comp":"OG000 vs OG001","p":"0.001"},{"comp":"OG000 vs OG002","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":129,"countries":["United States","Argentina","Brazil","Czechia","Hungary","Mexico","Puerto Rico","Romania","Russia","Slovakia","South Africa","South Korea","Ukraine"]},"refs":{"pmids":["26786577"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":237},"commonTop":["Headache","Influenza","Diarrhoea","Nasopharyngitis","Back Pain"]}}